Richard L. Kravitz, MD, MSPH and Jodi Halpern, MD, PhD
Patients have a responsibility to discerningly present the drug information they receive from direct-to-consumer advertising and to be active partners with their physician in making health care decisions.
Physicians are cautioned that the two obstacles to reforming post-marketing clinical trials are the FDA's reluctance to revisit past approvals and its inability to enforce pharmaceutical companies' commitment to conduct Phase IV trials.
A physician should protect the best interest of the patient and the patient's family in the event that an end-of-life case gains media attention and the treating physician and nontreating physicians are asked to comment.
A physician should protect the best interest of the patient and the patient's family in the event that an end-of-life case gains media attention and the treating physician and nontreating physicians are asked to comment.
Public health officials have a responsibility to alert the public to prospective dangers without unduly restricting individual freedom or adding to the stigmatization of certain illnesses.
Michael Farias, MD, MS, MBA and Rahul H. Rathod, MD
A distinguishing feature of a SCAMP is its ability to capture knowledge-based diversions from a recommended pathway and to “learn” from such individualized patient management.